Scientific article

Angiologie et hémostase : ce qui a changé en 2022

Published inRevue médicale suisse, vol. 19, no. 812, p. 199-201
Publication date2023-02-01

In this article, we have selected four topics that particularly caught our attention during the year 2022, and which are related to anticoagulation, its bleeding complications, and hemophilia. Thus, we discuss the issue of the treatment with rivaroxaban of atrial fibrillation associated with rheumatic valvulopathy, which has been studied in a randomized trial, the intensity of thromboprophylaxis in COVID outpatients and inpatients, and the bleeding risk of anticoagulation in patients with cerebral tumors. Finally, recent data on gene therapy in severe hemophilia A, an upcoming treatment, are discussed.

  • Humans
  • Anticoagulants / adverse effects
  • Venous Thromboembolism / drug therapy
  • COVID-19 / complications
  • Rivaroxaban / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / therapy
  • Hemostasis
  • Hemophilia A
  • Cardiology
  • Stroke / prevention & control
Citation (ISO format)
CASINI, Alessandro et al. Angiologie et hémostase : ce qui a changé en 2022. In: Revue médicale suisse, 2023, vol. 19, n° 812, p. 199–201. doi: 10.53738/REVMED.2023.19.812.199
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 08/02/2024
ISSN of the journal1660-9379

Technical informations

Creation10/04/2023 1:42:28 PM
First validation01/17/2024 12:37:11 PM
Update time01/17/2024 12:37:11 PM
Status update01/17/2024 12:37:11 PM
Last indexation05/06/2024 5:45:45 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack